4-(10,11-dibromo-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-piperidine → Desloratadine impurity 24

HRID 372159

Reaktionsgleichung

Reaktionsgleichung von HRID 372159
Br[CH:2]1[C:8]2[CH:9]=[CH:10][CH:11]=[CH:12][C:7]=2[C:6](=[C:13]2[CH2:18][CH2:17][NH:16][CH2:15][CH2:14]2)[C:5]2[CH:19]=[CH:20][CH:21]=[CH:22][C:4]=2[CH:3]1Br>O>[CH:22]1[C:4]2[CH2:3][CH2:2][C:8]3[CH:9]=[CH:10][CH:11]=[CH:12][C:7]=3[C:6](=[C:13]3[CH2:14][CH2:15][NH:16][CH2:17][CH2:18]3)[C:5]=2[CH:19]=[CH:20][CH:21]=1

Komponenten

3

Edukt 1

HCID 203283464-(10,11-dibromo-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-piperidine

Produkt 1

HCID 1201458Desloratadine impurity 24

Reagenzien, Katalysatoren, Lösungsmittel 1

HCID 962WaterLösungsmittel

Versuchsvorschrift

In accordance with the process of the present invention, the starting material, i.e., the 4-(10,11-dibromo-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-piperidine (I) is treated in an inert polar solvent with hydroxide ion, but preferably by dissolving the salt in water, to produce the biologically active 10,11-dihydroxy derivative of 4-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-piperidine (II). The product produced in this manner is biologically active and is a mixture of primarily the cis and trans isomers, the major portion being present in the cis configuration. The cis isomer of the compound may be isolated by selective fractional crystallization.

Quellen und Nachweise

ORD-Eintrag
ord-7c9e05974cec4258b28a75fbb768f20c
Quelldatensatz
uspto-grants-1978_05
Patentnummer
US04089864

Verknüpfte Notizen

Wird geladen…